Status:
UNKNOWN
Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Sepsis is responsible for 50% of all acute kidney injury (AKI) in intensive care units (ICUs), contributing greatly to multiple organ dysfunction syndrome (MODS). Special types of continuous renal rep...
Eligibility Criteria
Inclusion
- Male or female critically ill patients over the age of 18 years old
- Acute Kidney Injury requiring CRRT defined using the Risk, Injury, Failure, Loss, End-stage renal disease (RIFLE) classification with criterion I or worse.
- Septic shock as defined by the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.
- Written informed consent obtained from the patient or a patient's legal representative
- Patient patient's legal representative able to agree to patient's enrollment in the study with informed consent.
Exclusion
- Pregnancy
- Participation in another research study protocol
- Known heparin induced thrombopenia or contraindication to heparin
- Pre-existing chronic renal failure on chronic dialysis
- Therapeutic anticoagulation with heparin for another reason (e.g. chonic arrhythmia)
- Severe liver failure (15% prothrombin time)
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01839578
Start Date
May 1 2013
End Date
April 1 2015
Last Update
August 27 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Réanimation - Pavillon P, Hôpital Edouard Herriot
Lyon, France, 69003